Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06949605 · ClinicalTrials.gov registry record

Quantitative Xylazine Measurement in ED

A clinical trial of Substance Use Disorders and Opioid Overdose, sponsored by Icahn School of Medicine at Mount Sinai.

Recruiting
Registry status
15
Enrollment target
2
Study locations

NCT06949605: Recruiting study of Substance Use Disorders and Opioid Overdose, sponsored by Icahn School of Medicine at Mount Sinai.

NCT06949605 is a study of Substance Use Disorders and Opioid Overdose that is actively recruiting participants, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 15 participants, below the 500-participant average among 93 other Substance Use Disorders trials with a reported enrollment target (97% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06949605, a study of Substance Use Disorders and Opioid Overdose, is actively recruiting participants, sponsored by Icahn School of Medicine at Mount Sinai.

RECRUITING
Registry status
15 participants
Enrollment target
2
Study locations

Study Summary

Quantitative Xylazine Measurement Among Non-Fatal Opioid Overdose (OD) Patients in the Emergency Department (ED)

Primary Outcome

Concentration of Xylazine in blood as determined by lab.

Study Locations (2)

New York

  • NYC Health + Hospitals/Elmhurst - Elmhurst
  • Icahn School of Medicine - New York

Trial Details

FieldValue
Enrollment Target 15 participants
Start Date 2025-04-01
Est. Completion 2026-02-24

What NCT06949605 shows while recruiting

NCT06949605 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 500-participant average among 93 other Substance Use Disorders trials with a reported enrollment target (97% lower).

The record links to 2 conditions, with Substance Use Disorders appearing as the primary indexed condition, and to 0 interventions.

NCT06949605 reports a single indexed study location in New York.

Frequently Asked Questions

What is clinical trial NCT06949605 about?

NCT06949605 is a clinical study titled "Quantitative Xylazine Measurement in ED". Quantitative Xylazine Measurement Among Non-Fatal Opioid Overdose (OD) Patients in the Emergency Department (ED)

What is the current status of trial NCT06949605?

This trial is currently recruiting. The enrollment target is 15 participants. The study started on 2025-04-01. Estimated completion is 2026-02-24.

What conditions does trial NCT06949605 study?

This clinical trial studies the following conditions: Substance Use Disorders, Opioid Overdose.

Who is sponsoring clinical trial NCT06949605?

This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06949605 being conducted?

This trial has 2 study locations across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Substance Use Disorders

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06949605's enrollment target sits among peer trials

15 89th of 93 higher than 5 of 93 other Substance Use Disorders trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Substance Use Disorders trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01889381 · 15 participants · Phase 2

    Human Craniomaxillofacial Allotransplantation

  • NCT02530073 · 15 participants · NA

    Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH

  • NCT02535936 · 15 participants · NA

    Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy

  • NCT02918474 · 15 participants · NA

    Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06949605, the US trial registry maintained by the National Library of Medicine. NCT06949605 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.